CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 50 enrolled
Drug / intervention
Dipeptidyl peptidase-4 inhibitorsdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06021119
NCT06021119Phase 3Completed
CompareCT.gov

Feasibility of DPP-4 Inhibitor for the Treatment of Iftar-Related Glycemic Excursions in Patients With Type 1 Diabetes on MiniMed™ 780G Advanced Hybrid Closed Loop System

Ain Shams University·interventional·Posted Sep 1, 2023·Updated Sep 1, 2023

In Brief

A Phase 3 clinical trial evaluating Dipeptidyl peptidase-4 inhibitors for Time in Range. Completed, enrolled 50 participants across 1 site.

Detailed Summary

Background: Ramadan Iftar meal typically causes glucose excursions. Dipeptidyl peptidase-4 inhibitors increase serum concentrations of glucagon-like peptide-1 and thus, decrease blood glucose levels with low risk of hypoglycemia. Aim: To investigate the efficacy and safety of vildagliptin as an add-on therapy among adolescents and young adults with type 1 diabetes mellitus (T1DM) on glucose excursions of Iftar Ramadan meals and glycemic metrics during advanced hybrid closed-loop (AHCL) treatment.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsTime in Range
CountriesEgypt
Collaborators--

Timeline

Phase 3CompletedFinished
202420252026
First PostedSep 1, 2023
Enrollment StartMar 23, 2023
Primary CompletionApr 21, 2023
TodayJul 2, 2026
Enrollment to primary: 28 daysPosted 2.8 years ago

Interventions

Dipeptidyl peptidase-4 inhibitorsdrug

Dipeptidyl peptidase-4 inhibitors with Iftar meal